BUZZ-Orthocell hits highest since Dec 2021 on regulatory nod for sale in Singapore

Reuters
2024/10/08

** Shares of Orthocell Ltd rise as much as 10.4% to A$0.53, their highest since Dec 17, 2021

** Biotechnology firm says it has received a regulatory approval from the Health Sciences Authority in Singapore

** Co says approval is for OCC to commence sales of its nerve repair product, Remplir, in Singapore

** Adds, it is on track to receive U.S. FDA regulatory clearance in Q1 CY25

** OCC stock up 17.1% YTD

(Reporting by Ayushman Ojha in Bengaluru)

((Ayushman.ojha@thomsonreuters.com))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10